Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.
about
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complicationsLipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approachesPhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionLipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literaturen-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetesLipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemiaThe effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidismLipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valves.Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women.LDL cholesterol estimation in patients with the metabolic syndrome.Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosisCirculating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapyLipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart StudyRegulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station".The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome.Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemiaNon-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.Increased Small Dense LDL and Decreased Paraoxonase Enzyme Activity Reveals Formation of an Atherogenic Risk in Streptozotocin-Induced Diabetic Guinea Pigs.Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients.Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction.Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia.Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetesLipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.Cardiovascular disease risk prediction in women: is there a role for novel biomarkers?Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella.The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals.Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target.Lipoprotein-associated phospholipase A₂ mass level is increased in elderly subjects with type 2 diabetes mellitus.Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.
P2860
Q26777871-AAA124A4-558A-43A3-9D57-07F5A60835A0Q26866207-2115CA03-66C9-4BF3-A4B0-4826008795A2Q26997377-5A8F3FB3-5A65-4590-B815-8CAB6B18D2D7Q33536648-D0F136F0-881E-4D7E-A9B6-10AB5E490163Q33766630-BF990E99-F6B4-43DB-9D86-E4F53260DBB4Q33776187-15D640BC-735C-4195-BF89-6A2772263071Q33803486-588B66BA-BB55-4E2B-9CA0-ACAE728E4538Q33829154-1FEA76AC-6642-4C4C-9F61-66712D93C079Q33944562-BC5C29C6-3E1C-496C-B43B-1F4F445F0AE7Q33945132-B46EA24F-1C07-44FD-8891-30389C50F29EQ34188093-0DFB966F-D3F1-4785-A376-D684CBF9FA8AQ34410638-46A344BF-F60F-4F32-A89E-B36110F923EAQ34464823-7BA4B391-2172-4CE7-A299-7081189C0C8CQ34692452-17E4E596-754C-460B-8600-5ADDEB9A0465Q34770283-091A9328-66D1-48EC-B85A-51ED37C03420Q34776755-02D20D14-5DED-4643-A3F9-D32919D775B4Q34997089-A6F98572-4A3F-4BA3-A15C-4231B853EFD0Q35006841-8528F22B-065E-44E4-A4C7-65B9EE7636E4Q35267751-E1A2B037-6CF7-4AC8-BB3E-43EB6C122C91Q35841269-E56AA4E9-A235-4380-9215-F1B9833B15CDQ36071668-30B103CE-9127-4E0A-AF5A-A28A15F78E93Q36105683-8483DFF1-7B2C-4946-AC9E-66E4DDA0F83CQ36520326-C10466CD-C75B-4F14-8DCB-20303848CB6CQ36653658-6B02CA3C-9422-4599-982D-C654A6BD7D56Q36675450-5E8686BA-A603-48CE-9DE4-59A6E6F5A609Q36752159-2D6F2BE5-FEE9-4440-8A97-FA1DA61B95B9Q36825726-C82F0FAD-2CF2-4BBA-839F-2F33FB6FE8ADQ36843216-EC5AD30C-E56F-4843-9C9E-D2C1DA0E9519Q36913022-2DD8077A-C74B-497F-9230-33DD66189E7FQ36935414-91CF9677-7880-41F0-92A3-A3BC8C913109Q37112920-27590699-CCF5-4EDE-BCD3-761B2EFEEAACQ37244962-4CAFE9E2-6A8F-4ECF-9040-F153D742E2C5Q37299885-5D26BC9B-C3BD-47E5-B1F1-B9742F9FE535Q37305388-832E44EE-C8D5-4475-AA1C-66E080361D2CQ37424605-351AF761-27E2-4A9E-ABDA-C8C917D0CD14Q37430645-5B6AFF37-BD21-4096-9175-DB61F7AFD337Q37433102-C40938C0-E544-4D4D-A648-FCEC208A65F7Q37445865-B493A2DC-04D4-4CC3-95B7-39B618E18DF5Q37730748-B8E4FA4F-A89F-4233-A956-6B9ACAEB3A5FQ37857866-B6EEB69C-0376-4563-94CC-74F013C32B13
P2860
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Lipoprotein-associated phospho ...... LDL particles in human plasma.
@en
Lipoprotein-associated phospho ...... LDL particles in human plasma.
@nl
type
label
Lipoprotein-associated phospho ...... LDL particles in human plasma.
@en
Lipoprotein-associated phospho ...... LDL particles in human plasma.
@nl
prefLabel
Lipoprotein-associated phospho ...... LDL particles in human plasma.
@en
Lipoprotein-associated phospho ...... LDL particles in human plasma.
@nl
P2093
P1433
P1476
Lipoprotein-associated phospho ...... LDL particles in human plasma.
@en
P2093
Alexandros D Tselepis
Evangelia S Lourida
Irene Gazi
Moses Elisaf
Vasilis Tsimihodimos
P304
P356
10.1373/CLINCHEM.2005.058404
P407
P577
2005-10-13T00:00:00Z